Analysts’ recommendations and target price

Wall Street analysts expect an upside potential of 85.97% for Amarin (AMRN) based on the company’s closing price on March 26. In 2019, analysts have revised downwards the company’s target price from $34.00 in January and February to $32.60 in March. The current consensus analyst recommendation for the stock is a “strong buy.” To know about the key growth driver for Amarin, please read Vascepa Demand Drove Amarin’s Revenue in Fiscal 2018.

Analysts Lowered Target Price for Amarin in March

Of the five analysts covering Amarin, three are recommending a “strong buy,” and two are recommending a “buy.” On March 26, Amarin closed at $17.53, 0.11% higher than its previous closing price, 645.96% higher than its 52-week low of $2.35, and 24.88% lower than its 52-week high of $23.33. The company’s market capitalization is $6.19 billion.

Based on its closing price on March 26, Amarin has reported returns of -7.05% in the last week, -10.52% in the last month, and 32.50% in the last quarter. The company has reported returns of 486.29% in the last half year, 472.88% in the last year, and 28.80% YTD.

Revenue and EPS estimates

In its fourth quarter, Amarin reported revenues of $77.33 million, a YoY rise of 43.56%, and higher than the consensus estimate by $3.46 million. The company reported non-GAAP EPS of -$0.11, which was lower than the consensus estimate by $0.05.

Analysts expect Amarin’s revenues to change YoY by 53.24% to $67.30 million in the first quarter, 66.64% to $87.73 million in the second quarter, 72.17% to $95.25 million in the third quarter, and 48.97% to $115.20 million in the fourth quarter of 2019. Analysts also expect Amarin’s non-GAAP EPS to change YoY by -29.16% to -$0.10 in the first quarter, 50.0% to -$0.06 in the second quarter, 54.16% to -$0.04 in the third quarter, and 112.12% to $0.01 in the fourth quarter of 2019.

Analysts expect Amarin’s revenues to change YoY by 59.43% to $365.43 million in fiscal 2019, 55.26% to $567.35 million in fiscal 2020, and 47.30% to $835.73 million in fiscal 2021. Analysts also expect Amarin’s non-GAAP EPS to change YoY by 56.41% to -$0.17 in fiscal 2019, 242.12% to $0.24 in fiscal 2020, and 207.33% to $0.74 in fiscal 2021.

Latest articles

WeWork is gearing up for an IPO. On Wednesday, the company made its IPO filing with the SEC public and expects to garner $3.5 billion from its IPO.

After FCC Chairman Ajit Pai recommended the approval of the T-Mobile–Sprint merger, Representative David Cicilline urged the FCC to allow public comment.

Cresco Labs (CRLBF) is set to report its Q2 earnings on August 21 after the market closes. The company's stock fell 5.3% yesterday.

Cannabis stocks mostly traded in positive territory today. Supreme Cannabis (FIRE) and Aurora Cannabis (ACB) rose about 9.5% and 5.5%, respectively.

NVIDIA (NVDA) stock soared 6% in today’s trading session as its Q2 earnings for fiscal 2020 beat estimates. However, its guidance missed estimates.

Nio Inc. (NIO) has disrupted the automotive space since 2014 but only made waves in the market since its IPO. Investors have suffered numerous setbacks.